Compare OFLX & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFLX | DCTH |
|---|---|---|
| Founded | 1975 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.4M | 289.2M |
| IPO Year | 2005 | N/A |
| Metric | OFLX | DCTH |
|---|---|---|
| Price | $27.85 | $9.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $22.60 |
| AVG Volume (30 Days) | 33.6K | ★ 779.8K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.59 | 0.03 |
| Revenue | ★ $100,054,000.00 | $79,603,000.00 |
| Revenue This Year | N/A | $131.97 |
| Revenue Next Year | N/A | $38.84 |
| P/E Ratio | ★ $17.42 | $283.43 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $25.58 | $8.12 |
| 52 Week High | $48.58 | $18.23 |
| Indicator | OFLX | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 54.43 |
| Support Level | $26.84 | $9.25 |
| Resistance Level | $29.43 | $9.80 |
| Average True Range (ATR) | 1.00 | 0.46 |
| MACD | 0.28 | 0.18 |
| Stochastic Oscillator | 52.21 | 80.69 |
Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States. The company derives revenues from the manufacture and sale of flexible metal hose and accessories.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.